BMS’ Opdivo cuts risk of melanoma recurrence

According to data from the Phase III CheckMate-238 study, Bristol-Myers Squibb’s Opdivo (nivolumab) could significantly reduce the risk of a patient’s melanoma returning compared with Yervoy (ipilimumab). The study showed that at 24 months 63% of patients treated with Opdivo had recurrent-free survival, compared to 50% of patients treated with Yervoy, regardless of BRAF mutation status. At 18 months, Opdivo showed a lower rate of serious adverse events (AEs) of any grade at 17.5% compared to 40.4% for Yervoy.
Professor John Wagstaff, Professor of Medical Oncology, College of Medicine, Swansea University and UK trial investigator, said the data for Opdivo represent “a significant advance in how we could help prevent recurrence of this potentially deadly disease. With many melanoma patients being relatively young, it is critical treatment options are available for patients that could help to overcome their disease. These data show the potential for nivolumab in this patient group.”
Gill Nuttall, chief executive and founder of Melanoma UK said the landmark data could represent a significant step forward for patients, who can be left with limited treatment options after surgery.